Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model

  • Authors:
    • Mamoru Nukatsuka
    • Akio Fujioka
    • Fumio Nakagawa
    • Hideyuki Oshimo
    • Kenji Kitazato
    • Jyunji Uchida
    • Yoshikazu Sugimoto
    • Sekio Nagayama
    • Masakazu Fukushima
  • View Affiliations

  • Published online on: December 1, 2004     https://doi.org/10.3892/ijo.25.6.1531
  • Pages: 1531-1536
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To evaluate the antitumor and antimetastatic efficacy of oral fluoropyrimidines, alone and combined with taxane on human breast cancer xenografts model, we developed a breast cancer model that spontaneously metastasizes to the lung by orthotopic implantation of MDA-MB-435S-HM tumors into the mammary fat pad (mfp) of SCID mice. The activity of the 5-fluorouracil (5-FU)-degrading enzyme dihydropyrimidine dehydrogenase (DPD) was significantly higher in the metastatic tumors than in the primary tumors. Based on this enzymatic characteristic of pulmonary metastases of breast cancer in regard to 5-FU metabolism, we investigated the antitumor activity of two types of oral 5-FU prodrugs, with and without paclitaxel, on both orthotopically implanted breast tumors and metastatic lung tumors in mice. The drugs and doses used were: S-1, a new oral DPD-inhibiting fluoropyrimidine (DIF) 8.3 mg/kg/day, capecitabine 360 mg/kg/day as a non-DIF, and paclitaxel 50 mg/kg, all of which display minimal toxicity in mice. In the primary tumors, paclitaxel and S-1 displayed a significant antitumor activity, with 57 and 41%, respectively inhibition of tumor growth (p<0.01), but capecitabine had no effect. When S-1 and paclitaxel were combined, they synergistically caused tumor regression (tumor growth inhibition ratio 94%, p<0.01) in mice compared to capecitabine plus paclitaxel, without any toxicity. In the pulmonary metastasis model, paclitaxel, and both S-1 alone and combined with paclitaxel, but not capecitabine alone or combined with paclitaxel, diaplayed almost complete antimetastatic activity. These results strongly suggest that combination of S-1, as a DIF with taxanes will show a potent high antitumor and antimetastatic effect on refractory human breast cancers, especially those expresseing strong DPD activity.

Related Articles

Journal Cover

December 2004
Volume 25 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nukatsuka M, Fujioka A, Nakagawa F, Oshimo H, Kitazato K, Uchida J, Sugimoto Y, Nagayama S and Fukushima M: Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. Int J Oncol 25: 1531-1536, 2004
APA
Nukatsuka, M., Fujioka, A., Nakagawa, F., Oshimo, H., Kitazato, K., Uchida, J. ... Fukushima, M. (2004). Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. International Journal of Oncology, 25, 1531-1536. https://doi.org/10.3892/ijo.25.6.1531
MLA
Nukatsuka, M., Fujioka, A., Nakagawa, F., Oshimo, H., Kitazato, K., Uchida, J., Sugimoto, Y., Nagayama, S., Fukushima, M."Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model". International Journal of Oncology 25.6 (2004): 1531-1536.
Chicago
Nukatsuka, M., Fujioka, A., Nakagawa, F., Oshimo, H., Kitazato, K., Uchida, J., Sugimoto, Y., Nagayama, S., Fukushima, M."Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model". International Journal of Oncology 25, no. 6 (2004): 1531-1536. https://doi.org/10.3892/ijo.25.6.1531